首页 | 本学科首页   官方微博 | 高级检索  
     

恩替卡韦治疗慢性乙型重型肝炎临床观察
引用本文:林锋,吴涛,符健,吴彪,邱平,许小珍,蔡笃运,贾杰. 恩替卡韦治疗慢性乙型重型肝炎临床观察[J]. 中国热带医学, 2009, 9(4): 646-647,662
作者姓名:林锋  吴涛  符健  吴彪  邱平  许小珍  蔡笃运  贾杰
作者单位:海南省人民医院感染科,海南,海口,570311
摘    要:目的观察在内科综合治疗的基础上,用恩替卡韦治疗慢性乙型重型肝炎的疗效及安全性。方法37例慢性重型乙型肝炎患者随机分成为两组,治疗组20例患者在内科综合治疗的基础上加用恩替卡韦0.5mg/d治疗,对照组17例患者仅内科综合治疗。在治疗前和治疗6~8周后分别检测两组患者血清丙氨酸氨基转移酶(ALT)、总胆红素(TB)、白蛋白(ALB)、凝血酶原活动度(PTA)和HBV DNA。如患者治疗后症状消失或缓解,上述检查结果恢复者判断为有效,反之为无效。结果治疗组20例患者治疗有效14例,有效率为70%,对照组17例患者治疗有效6例,有效率为35.9%。两者比较有统计学意义(P〈0.05)。治疗组患者经6~8周治疗后患者血清ALT、TB和HBV DNA较治疗前明显下降(P〈0.05),ALB和PTA较治疗前明显上升(P〈0.05),均有统计学意义。对照组患者经6~8周治疗后患者血清ALT、TB较治疗前下降,但无统计学意义(P〉0.05);HBV DNA、ALB和PTA较治疗前变化均无统计学意义(P〉0.05)。治疗组患者口服恩替卡韦0.5mg/d治疗6~8周后未出现不良反应。结论在内科综合治疗的基础上,恩替卡韦治疗慢性重型乙型肝炎安全且有效。

关 键 词:恩替卡韦  慢性重型肝炎

Observation of efficacy and safety of enticavir in treatment of acute on chronic hepatitis B
LIN Feng,WU Tao,FU Jian,et al.. Observation of efficacy and safety of enticavir in treatment of acute on chronic hepatitis B[J]. China Tropical Medicine, 2009, 9(4): 646-647,662
Authors:LIN Feng  WU Tao  FU Jian  et al.
Affiliation:Dept.of Infectious Diseases.Hainan Provincial People's Hospital.Haikou 570311;Hainan;P.R.China
Abstract:Objective To evaluate the clinical efficacy and safety of enticavir(ETV) in treatment of acute on chronic hepatitis B.Methods 37 patients with acute on chronic hepatitis B were randomly divided into treatment group consisted of 20 patients and treated with ETV plus inter medicine and control group consisted of 17 patients and treated only with inter medicine.Levels of of serum ALT,total bilirubin(TB),albumin(ALB),prothrombin activities(PTA) and HBV DNA in patients of both groups were detected before and aft...
Keywords:ETV  Acute on chronic hepatitis B  
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号